Ablynx N.v.

Innogenetics N.v.

Boehringer Ingelheim International Gmbh

Vectura Gmbh

Vib Vzw

N.v. Innogenetics S.a.

Innogentics N.v.

N.v. Innogenetics

Erik Depla

Catelijne Stortelers

Geert Maertens

Diane Van Hoorick

Alisa K Waterman

Sanjaya Singh

Toon Laeremans

Peter Vanlandschoot

Marie-Ange Buyse

Erwin Sablon

Fons Bosman

Cedric Jozef Néotère Ververken

Jose Melero

Stephanie Staelens

Peter Casteels

Xavier Saelens

Bert Schepens

Joachim Boucneau

Rene Georg Ott

Andreas Gschwind

Geert Deschamps

Mauro Sergi

Karen Silence

Hans De Haard

Tobias Kolb

Martin Huber

Bernhard Müllinger

Marie-Paule Lucienne Armanda Bouche

Stefan De Buck

Mark Vaeck

Paul M P Van Bergen En Henegouwen

Alfons Bosman

Koen Allosery

Juliane Schick

Pascal Merchiers

Gert Verheyden

Annie Van Broekhoven

Isabelle Samson

Johannes Joseph Wilhelmus De Haard

Michael John Scott Saunders

Cedric Jozef Neotere Ververken

Francis Descamps

Alexander Szyroki

Anna Hultberg

Steve Schoonooghe

Daniel Janssen

Frank Kamiel Delphina Verdonck

Manfred Suckow

Gholamreza Hassanzadeh Ghassabeh

Massimiliano Germani

Maria-Laura Sargentini

Veerle Delanote

Bram Maassen

Mark Edward Labadia

Cornelis Theodorus Verrips

Steven Van Gucht

Ann Mikhail

Robert Anthony Weiss

Nigel J Temperton

Michael Marie Harmsen

Stany Depraetere

Joost Haelewyn

Frans Van Wijnendaele

Eric Borges

Marie-Paule Lucienne Bouche

Samjaya Singh

Bernhard MÜLLINGER

Nigel James Temperton

Frederik Stevenaert

The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.

Nucleic acids encoding CX3CR1-binding polypeptides comprising immunoglobulin single variable domains

The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.

Methods and compositions for the preparation of aerosols

The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.

Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases

CX3CR1-binding polypeptides comprising immunoglobulin single variable domains

Bispecifc binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.

Bispecific binding molecules binding to VEGF and Ang2

The present invention relates to polypeptides comprising an immunoglobulin variable domain, binding with high affinity to serum albumin for increasing the half-life of therapeutic agents and compositions, in particular for therapeutic agents comprising multispecific immunoglobulin variable domains. Also provided herein are methods for the production of polypeptides comprising serum albumin binding immunoglobulin variable domains of the present invention.

Serum albumin binding agents

The present invention relates to immunoglobulins that specifically bind Kv1.3 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Kv1.3.

KV1.3 binding immunoglobulins

Amino acid sequences are provided that are directed against/and or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes.

Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections

Methods are provided for the treatment of RSV infections in young children. More specifically, methods are provided wherein polypeptides that bind F protein of hRSV and that neutralize RSV infection are administered to the lungs of young children at specific dose regimens.

Methods of treating RSV infections

An inhalation device, assembly or system can include a kit and a pharmaceutical composition. The device can be adapted for administering therapeutic aerosols to pediatric patients, including neonates, infants or toddlers. The device can further include a vibrating mesh aerosol generator that can be insertable into a flow channel of the inhalation device through a lateral opening, and a valved face mask. The device can be connectable to a gas source through which a gas, such as oxygen, can be received into the flow channel at a low flow rate.

Inhalation device for use in aerosol therapy of respiratory diseases

Bispecific binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.

Growing community of inventors

Destelbergen, Belgium

Erik Depla